PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 446500

Transitional cell carcinoma arising from bladder left behind.

S Asano·M Matsuda·M Takemoto·M Osafune·S Sagawa
View original source ↗Export metadata ↓

Abstract

A case of transitional cell carcinoma arising from a bladder which was left behind for more than 24 years without pyocystis syndrome is described. A search in the literature revealed 10 cases of defunctionalized bladder that developed tumors over a rather short latent period ranging from 3 months to 7 years, and mostly with evidence of severe bladder infection.

Explore related subjects

Carcinoma, Transitional CellHumansMaleMiddle AgedUrinary Bladder NeoplasmsUrinary DiversionCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Asano, M Matsuda, M Takemoto, M Osafune, S Sagawa. 1979. Transitional cell carcinoma arising from bladder left behind.. https://doi.org/10.1159/000473114

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Trimodality treatment and selective organ preservation for bladder cancer.

Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment, including transurethral resection of the bladder tumor (TURBT), radiation therapy and chemotherapy, has been shown to produce survival rates comparable to those of cystectomy. With these programs, cystectomy has been reserved for patients with incomplete response or local relapse. During the past 15 years, organ preservation by trimodality treatment has been investigated in prospective series from single centers and cooperative groups, with more than 1,000 patients included. Five-year overall survival rates in the range of 50% to 60% have been reported, and approximately three quarters of the surviving patients maintained their bladder. Clinical criteria helpful in determining ideal patients for bladder preservation include early tumor stage (including high-risk T1 disease), a visibly complete TURBT, and absence of ureteral obstruction. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on (1) optimizing radiation techniques and incorporating more effective systemic chemotherapy, and (2) the proper selection of patients based on molecular makers.

Carcinoma, Transitional Cell↗